Funding - July 7, 2026
Wallenberg Proof-of-Concept program backs 17 Swedish innovation projects
The Knut and Alice Wallenberg Foundation has awarded Proof-of-Concept grants to ten life science innovation projects in collaboration with SciLifeLab, alongside seven projects in AI, quantum technologies and ICT, strengthening the route from frontier academic research to commercial and societal impact across Sweden.
Collaboration - July 6, 2026
Mavatar enters research collaboration with Clínica Universidad de Navarra
Mavatar has announced a research collaboration with the group of Bruno Paiva, Director of Flow Cytometry at Clínica Universidad de Navarra and Principal Investigator of the Translational Immunomics in Hematological Neoplasms Research Group at Cima Universidad de Navarra, Spain.
Europe - July 6, 2026
New European initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).
Science article - July 5, 2026
Progress in smell and taste research
Imagine walking into a bakery with ovens full of fragrant bread and smelling… nothing. Or taking a bite out of a spicy sausage, which to you has as much flavor as cardboard.
Agreement - July 3, 2026
AlzeCure enters an out-licensing and collaboration agreement with QuantumCell
AlzeCure Pharma has entered into an out-licensing and collaboration agreement with QuantumCell, a Danish tech-enabled biotech company, regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856.
Pharma Business - July 3, 2026
AstraZeneca’s Enhertu approved in the EU
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors who have received prior treatment and who have no satisfactory treatment options.
